Trichomoniasis — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Trichomoniasis, a sexually transmitted infection (STI), results from the presence of a parasitic organism known as trichomonas vaginalis. This infection is a frequent cause of symptomatic vaginitis in women residing in the lower genitourinary tract of females and the prostate and urethra of males, with many infected men exhibiting no symptoms. Transmission of trichomoniasis occurs primarily through direct sexual contact, and although the parasite can survive briefly in moist environments, the vast majority of cases stem from venereal transmission. Risk factors encompass a history of STIs, engaging with new or multiple sex partners, contact with an infected partner, intravenous drug abuse, and the absence of barrier contraception. In women, the incubation period for T. vaginalis ranges from five to twenty-eight days. Symptoms in women often include a malodorous yellow or green vaginal discharge, dyspareunia, urinary frequency, dysuria, and vulvar pruritus or erythema. Conversely, men frequently remain asymptomatic, but if symptoms manifest, urethritis is the most common, with prostatitis and epididymitis occurring less frequently. Untreated trichomoniasis during pregnancy can lead to significant morbidity, contributing to preterm delivery, low birth weight infants, and premature rupture of membranes.
- In the United States, the prevalence of Trichomonas vaginalis is 2.1% among women aged 14–59 and 0.5% among men.
Thelansis’s “Trichomoniasis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Trichomoniasis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Trichomoniasis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Trichomoniasis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
